

Clinical Trial Protocol

Iranian Registry of Clinical Trials

22 Jun 2026

The evaluation of esomeprazole efficacy in treatment of early onset pre-eclampsia

Protocol summary

Summary

Objective: Determination of esomeprazole efficacy in treatment of early onset pre-eclampsia. Design: Forty six pregnancy women that suffer to preeclampsia with a gestational age of 26 to 32 weeks are entered in this study. Patients are randomly assigned to two groups according to a random number table generated by the computer. Since this study can be effective in reducing side effects, this study is phase 3. Setting and conduct: This study is a prospective clinical trial, single blind and randomized control group (placebo) that will be performed in the Hospitals of Mashhad University of Medical Sciences onto pregnant women who suffer to preeclampsia with a gestational age of 26 to 32 weeks will be done.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017082333680N2**

Registration date: **2017-10-22, 1396/07/30**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2017-10-22, 1396/07/30

Registrant information

Name

Farideh Golhasani

Name of organization / entity

Mashhad University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 51 3802 2631

Email address

golhasanif1@mums.ac.ir

Recruitment status

Recruitment complete

Funding source

Mashhad University of Medical Sciences

Expected recruitment start date

2017-10-23, 1396/08/01

Expected recruitment end date

2018-10-23, 1397/08/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The evaluation of esomeprazole efficacy in treatment of early onset pre-eclampsia

Public title

The evaluation of esomeprazole efficacy in treatment of early onset pre-eclampsia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Preeclampsia diagnosis; hypertensive pregnancy; gestational age between 26 to 32 weeks; single-crowned pregnancy; no need to terminate the pregnancy in the next 48 hours; absence of anomalies in the fetus; patient satisfaction for expected treatment; Exclusion criteria: Eclampsia; uncontrolled blood pressure; pulmonary edema; cerebrovascular accidents; heart failure; HELLP syndrome; use of proton pump inhibitors; renal failure; uncertain tests for the evaluation of embryo's health

Age

From **18 years** old to **50 years** old

Gender

Female

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: 46

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mashhad University of Medical sciences

Street address

Mashhad University of Medical Sciences, International Office Administration Center(Qoreishi Building), Daneshgah St.

City

Mashhad

Postal code

9138813944

Approval date

2017-04-18, 1396/01/29

Ethics committee reference number

IR.MUMS.fm.REC.1396.40

Health conditions studied

1

Description of health condition studied

Preeclampsia

ICD-10 code

O15.0

ICD-10 code description

Eclampsia in pregnancy

Primary outcomes

1

Description

Duration of admission to delivery

Timepoint

before intervention until delivery

Method of measurement

Pregnancy termination

Secondary outcomes

1

Description

Frequency of maternal and fetal complications in patients with preeclampsia

Timepoint

before intervention until delivery

Method of measurement

Questionnaire and checklist

2

Description

Biomarker level of tyrosine kinase and endoglycine

Timepoint

after Intervention

Method of measurement

Blood test

Intervention groups

1

Description

The intervention group received 12 mg Betamethasone in two doses every 24 hours plus prescribed 40 mg osmoparazole daily.

Category

Treatment - Drugs

2

Description

The control group received 12 mg Betamethasone in two doses every 24 hours plus prescribed 40 mg placebo daily.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Emam Reza Hospital

Full name of responsible person

Seyedeh Azam Pourhoseini

Street address

Department of Obstetrics and Gynecology, Imam Reza Hospital, Taghiabad Square

City

Mashhad

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Mashhad University of Medical Sciences

Full name of responsible person

Dr. Mahyar Mirheidari

Street address

Mashhad University of Medical Sciences, International Office Administration Center(Qoreishi Building), Daneshgah St.

City

Mashhad

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor for research, Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact**Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr. Shourvarzi

Position

Resident of Obstetrics and Gynecology

Other areas of specialty/work**Street address**

Department of Obstetrics and Gynecology, Imam Reza Hospital. Taghi-Abad Square,

City

Mashhad

Postal code

9137913316

Phone

+98 51 3802 2608

Fax**Email**

sheida20shoorvarzi@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Dr. Mirzaeian

Position

Assistant professor of Obstetrics and Gynecology

Other areas of specialty/work**Street address**

Department of Obstetrics and Gynecology, Imam Reza Hospital, Square Taghi-Abad.

City

Mashhad

Postal code

9137913316

Phone

+98 51 3802 2608

Fax**Email**

mirzaeians@mums.ac.ir

Web page address

Person responsible for updating data

Contact**Name of organization / entity**

Mashhad University of Medical Sciences

Full name of responsible person

Farideh Golhasani

Position

Master

Other areas of specialty/work**Street address**

Woman Health Research Center, Imam Reza Hospital, Taghiabad Square.

City

Mashhad

Postal code

9137913316

Phone

+98 51 3853 8659

Fax**Email**

golhasanif1@mums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty